(24/7 MARKET NEWS) – Aspira Women’s Health Inc. (NASDAQ: AWH) reported, this morning, that one of the nation’s top national health insurance companies, with over 80 million lives worldwide, agreed to extend coverage to OvaWatch, Aspira’s new ovarian cancer test launched by the Company in December 2022. The plan covered the Ova1Plus test for its members for the past several years and this coverage decision ensures OvaWatch will be provided on an in-network basis for the plan’s members minimizing their out of pocket expenses. The coverage decision was based on the latest published evidence demonstrating the clinical validation of OvaWatch.
Aspira Women’s Health is at $0.42, up $0.07 (+20.00%), on 50 thousand premarket shares.
Its 52-week trading range is $0.285 to $1.26. Its next key resistance points are $0.48, $0.55 and $0.60. If it can break through the $0.60 resistance and its trading volume gets much stronger, it may try to refill the gap to the $0.80+ trading level.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
